TECH vs NEOG

For growth investors, Bio-Techne Corporation (TECH) is the stronger pick with 5.

2% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Bio-Techne Corporation (TECH) offers the better valuation at 103. 1x trailing P/E (23. 9x forward), making it the more compelling value choice. Analysts rate Bio-Techne Corporation (TECH) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bio-Techne Corporation is actually cheaper at 23.

9x.

Over the past 5 years, Bio-Techne Corporation (TECH) delivered a total return of -52.

3%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: TECH returned +100. 6% versus NEOG's -49. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Techne Corporation (TECH) is the lower-risk stock at 1.

41β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 30% more volatile than TECH relative to the S&P 500. On balance sheet safety, Bio-Techne Corporation (TECH) carries a lower debt/equity ratio of 23% versus 44% for Neogen Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bio-Techne Corporation (TECH) is pulling ahead at 5.

2% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Bio-Techne Corporation grew EPS -56. 2% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Techne Corporation (TECH) is the more profitable company, earning 6.

0% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TECH leads at 8. 4% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — TECH leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bio-Techne Corporation (TECH) trades at 23.

9x forward P/E versus 25. 7x for Neogen Corporation — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TECH: 46. 3% to $69. 33.

In this comparison, TECH (0.

7% yield) pays a dividend. NEOG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

7% yield, +100. 6% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECH: +100. 6%, NEOG: -49. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TECH pays a dividend while NEOG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.